Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 5 (2008), Issue 1 (January)

1. Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCaP).
   Int J Cancer, 122(5): 1145-54. [Abstract] [Full-text]
2. Polymorphic CAG and GGC repeat lengths in the androgen receptor gene and prostate cancer risk: analysis of a Brazilian population.
   Cancer Invest, 26(1): 74-80. [Abstract] [Full-text]
3. Complications and limitations related to periprostatic local anesthesia before TRUS-guided prostate biopsy.
   J Clin Ultrasound, 36(2): 67-71. [Abstract] [Full-text]
4. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.
   J Clin Oncol, 26(2): 242-5. [Abstract] [Full-text]
5. Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer.
   BJU Int, 101(3): 308-12. [Abstract] [Full-text]
6. The economic and workload impact of 'backdoor' prostate-specific antigen screening on the UK National Health Service: a single-centre experience.
   BJU Int, 101(3): 289-92. [Abstract] [Full-text]
7. Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes.
   Cancer, 112(2): 307-14. [Abstract] [Full-text]
8. Characterization of calcium-independent purinergic receptor-mediated apoptosis in hormone-refractory prostate cancer.
   BJU Int, 101(3): 352-9. [Abstract] [Full-text]
9. Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel.
   Cancer, 112(2): 326-30. [Abstract] [Full-text]
10. The outcome of patients with pathological Gleason score >or=8 prostate cancer after radical prostatectomy.
    BJU Int, 101(3): 305-7. [Abstract] [Full-text]
11. Computer-aided ultrasonography (HistoScanning): a novel technology for locating and characterizing prostate cancer.
    BJU Int, 101(3): 293-8. [Abstract] [Full-text]
12. Secondary hormonal therapy for prostate cancer: what lies on the horizon?
    BJU Int, 101(3): 271-4. [Abstract] [Full-text]
13. Can non-malignant biopsy features identify men at increased risk of biopsy-detectable prostate cancer at re-screening after 4 years?
    BJU Int, 101(3): 283-8. [Abstract] [Full-text]
14. Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8-10 cancers.
    BJU Int, 101(3): 299-304. [Abstract] [Full-text]
15. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer.
    Oncogene, 27(3): 253-63. [Abstract] [Full-text]
16. MAD2DeltaC induces aneuploidy and promotes anchorage-independent growth in human prostate epithelial cells.
    Oncogene, 27(3): 347-57. [Abstract] [Full-text]
17. Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes.
    Science, 319(5860): 215-20. [Abstract] [Full-text]
18. Selective prostate cancer thermal ablation with laser activated gold nanoshells.
    J Urol, 179(2): 748-53. [Abstract] [Full-text]
19. Association of polymorphisms in TGFB1 and prostate cancer prognosis.
    J Urol, 179(2): 754-8. [Abstract] [Full-text]
20. Small transrectal ultrasound volume predicts clinically significant Gleason score upgrading after radical prostatectomy: results from the SEARCH database.
    J Urol, 179(2): 523-7; discussion 527-8. [Abstract] [Full-text]
21. Significance of tertiary Gleason pattern 5 in Gleason score 7 radical prostatectomy specimens.
    J Urol, 179(2): 516-22; discussion 522. [Abstract] [Full-text]
22. The 20-core prostate biopsy protocol--a new gold standard?
    J Urol, 179(2): 504-7. [Abstract] [Full-text]
23. CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer.
    J Urol, 179(2): 529-34; discussion 534-5. [Abstract] [Full-text]
24. The role of pelvic lymphadenectomy for prostate cancer--therapeutic?
    J Urol, 179(2): 408-13. [Abstract] [Full-text]
25. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy.
    J Urol, 179(2): 414-23. [Abstract] [Full-text]
26. Prostate volume estimation using the ellipsoid formula consistently underestimates actual gland size.
    J Urol, 179(2): 501-3. [Abstract] [Full-text]
27. The usefulness of the detection of GSTP1 methylation in urine as a biomarker in the diagnosis of prostate cancer.
    J Urol, 179(2): 508-11; discussion 511-2. [Abstract] [Full-text]
28. Polymorphisms in genes regulating androgen activity among prostate cancer low-risk Inuit men and high-risk Scandinavians.
    Int J Androl, 31(1): 25-30. [Abstract] [Full-text]
29. Cancer immunotherapy based on recombinant Salmonella enterica serovar Typhimurium aroA strains secreting prostate-specific antigen and cholera toxin subunit B.
    Cancer Gene Ther, 15(2): 85-93. [Abstract] [Full-text]
30. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth.
    Cancer Res, 68(2): 521-9. [Abstract] [Full-text]
31. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.
    Oncogene, 27(4): 506-18. [Abstract] [Full-text]
32. Fibroblast growth factor-2 mediates transforming growth factor-beta action in prostate cancer reactive stroma.
    Oncogene, 27(4): 450-9. [Abstract] [Full-text]
33. Effect of neoadjuvant epirubicin and total androgen blockade on complete pathological response in patients with clinical stage T3/T4 prostate cancer.
    Eur J Surg Oncol, 34(2): 216-21. [Abstract] [Full-text]
34. Long-term treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: analysis of radiation therapy oncology group studies 85-31, 86-10, and 92-02.
    Int J Radiat Oncol Biol Phys, 70(2): 437-41. [Abstract] [Full-text]
35. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy.
    Int J Radiat Oncol Biol Phys, 70(2): 425-30. [Abstract] [Full-text]
36. A cone beam CT-Based Study for Clinical Target Definition Using Pelvic Anatomy During Postprostatectomy Radiotherapy.
    Int J Radiat Oncol Biol Phys, 70(2): 431-6. [Abstract] [Full-text]
37. Salvage hypofractionated radiotherapy for biochemically recurrent prostate cancer after radical prostatectomy.
    Int J Radiat Oncol Biol Phys, 70(2): 449-55. [Abstract] [Full-text]
38. Offering a treatment choice in the irradiation of prostate cancer leads to better informed and more active patients, without harm to well-being.
    Int J Radiat Oncol Biol Phys, 70(2): 442-8. [Abstract] [Full-text]
39. Prostate cancer imaging.
    Acta Radiol, 49(1): 107-20. [Abstract] [Full-text]
40. No association between polymorphism in the vascular endothelial growth factor gene at position -460 and sporadic prostate cancer in the Turkish population.
    Mol Biol Rep, 35(1): 17-22. [Abstract] [Full-text]
41. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
    JAMA, 299(3): 289-95. [Abstract] [Full-text]
42. The roles of PET and PET/CT in the diagnosis and management of prostate cancer.
    Oncology, 72(3): 226-33. [Abstract] [Full-text]
43. Methyl 2-cyano-3,11-dioxo-18 beta-olean-1,12-dien-30-oate is a peroxisome proliferator-activated receptor-gamma agonist that induces receptor-independent apoptosis in LNCaP prostate cancer cells.
    Mol Pharmacol, 73(2): 553-65. [Abstract] [Full-text]
44. Hepatocyte nuclear factor-3 alpha (HNF-3alpha) negatively regulates androgen receptor transactivation in prostate cancer cells.
    Biochem Biophys Res Commun, 367(2): 481-6. [Abstract] [Full-text]
45. Anterior-predominant prostatic tumors: zone of origin and pathologic outcomes at radical prostatectomy.
    Am J Surg Pathol, 32(2): 229-35. [Abstract] [Full-text]
46. hCAP-D3 expression marks a prostate cancer subtype with favorable clinical behavior and androgen signaling signature.
    Am J Surg Pathol, 32(2): 205-9. [Abstract] [Full-text]
47. Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging--correlation with pathologic findings.
    Radiology, 246(2): 480-8. [Abstract] [Full-text]
48. Human PARM-1 is a novel mucin-like, androgen-regulated gene exhibiting proliferative effects in prostate cancer cells.
    Int J Cancer, 122(6): 1229-35. [Abstract] [Full-text]
49. Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer.
    Int J Cancer, 122(6): 1400-10. [Abstract] [Full-text]
50. Prevalence, severity, and impact of symptoms on female family caregivers of patients at the initiation of radiation therapy for prostate cancer.
    J Clin Oncol, 26(4): 599-605. [Abstract] [Full-text]
51. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.
    J Clin Oncol, 26(4): 585-91. [Abstract] [Full-text]
52. A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer.
    BJU Int, 101(4): 436-9. [Abstract] [Full-text]
53. Paraneoplastic Cushing's syndrome in prostate cancer: a difficult management problem.
    BJU Int, 101(4): 424-7. [Abstract] [Full-text]
54. The rs743572 common variant in the promoter of CYP17A1 is not associated with prostate cancer risk or circulating hormonal levels.
    BJU Int, 101(4): 492-6. [Abstract] [Full-text]
55. Efficacy of low-dose dexamethasone in castration-refractory prostate cancer.
    BJU Int, 101(4): 440-3. [Abstract] [Full-text]
56. The use of an endoscopic stapler vs suture ligature for dorsal vein control in laparoscopic prostatectomy: operative outcomes.
    BJU Int, 101(4): 463-6. [Abstract] [Full-text]
57. Rationale and clinical implication of combined chemotherapy with cisplatin and oestrogen in prostate cancer: primary evidence based on methylation analysis of oestrogen receptor-alpha.
    BJU Int, 101(4): 485-91. [Abstract] [Full-text]
58. Shear-induced intracellular loading of cells with molecules by controlled microfluidics.
    Biotechnol Bioeng, 99(4): 846-54. [Abstract] [Full-text]
59. The antibody response to Propionibacterium acnes is an independent predictor of serum prostate-specific antigen levels in biopsy-negative men.
    BJU Int, 101(4): 429-35. [Abstract] [Full-text]
60. Epidermal growth factor upregulates motility of Mat-LyLu rat prostate cancer cells partially via voltage-gated Na+ channel activity.
    J Cell Physiol, 215(1): 77-81. [Abstract] [Full-text]

© 2004-2008 Prostate Cancer Research Today. All Rights Reserved.